HK Stock Market Move | SINOPHARM(01099) rises over 5%, temporarily leading gains among blue-chip stocks; net profit attributable to shareholders for the first three quarters edged up year-on-year.
Sinopharm Group (01099) rose over 5%, temporarily leading gains among blue-chip stocks. As of press time, it was up 5.41% at HK$16.17, with a turnover of approximately HK$80.5257 million.
SINOPHARM(01099) rose over 5%, temporarily leading gains among blue-chip stocks. As of press time, it was up 5.41% at HK$16.17, with a turnover of approximately HK$80.5257 million.
On the news front, SINOPHARM released its results for the nine months ended September 30, 2026. The company recorded operating revenue of RMB427.613 billion, down 0.9% year-on-year; net profit attributable to shareholders was RMB5.314 billion, up 0.13% year-on-year. Third-quarter revenue was RMB144.814 billion, with the year-on-year decline narrowing to 0.43%; third-quarter net profit attributable to shareholders was RMB1.910 billion, up 3.74% year-on-year. In the first three quarters, selling, administrative and financial expenses fell 5.93%, 3.41% and 20.95%, respectively, while credit impairment losses narrowed from RMB1.901 billion to RMB1.583 billion.
Related Articles
TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical's net profit attributable to shareholders for the first three quarters was RMB78.51 million, down 78.82% year-on-year.
H&H INTL HLDG (01112): Total revenue for the first three quarters rose 24.5% year on year on a reported basis.
LONG INV CORP (02312): Issuance of 204 million new shares under rights issue
TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical's net profit attributable to shareholders for the first three quarters was RMB78.51 million, down 78.82% year-on-year.
H&H INTL HLDG (01112): Total revenue for the first three quarters rose 24.5% year on year on a reported basis.
LONG INV CORP (02312): Issuance of 204 million new shares under rights issue
